Abstract
We conducted a phase II study to determine the response rate and toxicity of weekly docetaxel and a flat dose capecitabine (days 5–18 of the 28-day cycle) in patients with incurable locally recurrent or metastatic head and neck cancers. The responses at 4 months were analyzed among 36 patients. Although the response rate was modest (11%), the 6.5 months estimated median survival was comparable to the standard platinum and 5-FU combination regimens. Major grade 3 and 4 toxicities included lymphopenia, infection, and fatigue. In view of low efficacy, this particular regimen does not appear to warrant further study.
Publication types
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Capecitabine
-
Case-Control Studies
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives
-
Disease-Free Survival
-
Docetaxel
-
Drug Administration Schedule
-
Fatigue / chemically induced
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / adverse effects
-
Fluorouracil / analogs & derivatives
-
Head and Neck Neoplasms / drug therapy*
-
Head and Neck Neoplasms / pathology
-
Humans
-
Lymphopenia / chemically induced
-
Male
-
Middle Aged
-
Neoplasm Metastasis
-
Neoplasm Recurrence, Local
-
Taxoids / administration & dosage
-
Taxoids / adverse effects
-
Treatment Outcome
Substances
-
Taxoids
-
Deoxycytidine
-
Docetaxel
-
Capecitabine
-
Fluorouracil